Literature DB >> 6734455

[Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study].

E Schneider, P A Fischer, R Clemens, F Balzereit, E W Fünfgeld, H J Haase.   

Abstract

The effectiveness of memantine on the symptoms of Parkinson's disease was investigated in 67 patients (39 males, 28 females) mostly between 55 and 75 years. The study was multi-center placebo-controlled with four treatment groups, i. e. patients with and without pre- and after-treatment with other anti-Parkinson medication receiving either placebo or memantine as sole or additional medication. The analysis of 61 evaluable cases showed a positive statistically significant influence on the single symptom tremor as well as on the neurological overall symptomatology (Webster-scale total score). Despite the inadequately ascertained mode of action memantine promises success particularly in milder and initial forms of the Parkinson syndrome either used as monotherapy or as an adjuvant.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734455     DOI: 10.1055/s-2008-1069311

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  18 in total

Review 1.  Neuroprotection in glaucoma: drug-based approaches.

Authors:  William Cheung; Li Guo; M Francesca Cordeiro
Journal:  Optom Vis Sci       Date:  2008-06       Impact factor: 1.973

2.  Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats.

Authors:  O A Andreassen; T O Aamo; H A Jøorgensen
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

3.  Neuroanatomical correlates of the inhibition of tremulous jaw movements in rats by a combination of memantine and Δ9 -tetrahydrocannabinol.

Authors:  Ilya D Ionov; Irina I Pushinskaya; David D Frenkel; Niсholas P Gorev; Larissa A Shpilevaya
Journal:  Br J Pharmacol       Date:  2020-01-24       Impact factor: 8.739

4.  Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells.

Authors:  I Bresink; T A Benke; V J Collett; A J Seal; C G Parsons; J M Henley; G L Collingridge
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

5.  Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism.

Authors:  H S Chen; S A Lipton
Journal:  J Physiol       Date:  1997-02-15       Impact factor: 5.182

6.  Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices.

Authors:  T Frankiewicz; B Potier; Z I Bashir; G L Collingridge; C G Parsons
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

7.  A Validated Stability-indicating Reverse Phase HPLC Assay Method for the Determination of Memantine Hydrochloride Drug Substance with UV-Detection Using Precolumn Derivatization Technique.

Authors:  Bhavil Narola; A S Singh; P Rita Santhakumar; T G Chandrashekhar
Journal:  Anal Chem Insights       Date:  2010-07-20

8.  High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats.

Authors:  W Löscher; D Hönack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-05       Impact factor: 3.000

Review 9.  Glutamate receptors and Parkinson's disease: opportunities for intervention.

Authors:  Michael J Marino; Ornella Valenti; P Jeffrey Conn
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.

Authors:  Stuart J Thomas; George T Grossberg
Journal:  Clin Interv Aging       Date:  2009-10-12       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.